Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unimed's Marinol

Executive Summary

Shipments of the antinausea agent Marinol (dronabinol) to "selected regional markets" began the week of July 14. The cannabinoid anti-emetic for cancer chemotherapy patients was approved in June 1985. However, the Drug Enforcement Agency did not complete rescheduling of the drug from Schedule I to Schedule II until April ("The Pink Sheet" April 7, T&G-2). Under a previously announced marketing agreement, Roxane will be responsible for final packaging, marketing and distribution of the drug.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS010489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel